Page 196 - Demo

Chapter 7194SampleWe studied data of 112 patients (mean age 32.5±12.4 years, 45% male) with a molecularly confirmed 22q11.2 deletion. Patients were ascertained through referrals from five main sources, from most to least frequent: family medicine, intellectual disability medicine, paediatrics, psychiatry, and medical genetics.Outcome measuresWe recorded information on demographic variables, cognitive functioning (full-scale intelligence quotient; FSIQ), and psychiatric history. A clinical diagnosis of PTSD was the primary outcome measure. We also recorded traumatic events, defined as in the Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5) subsection A of PTSD (i.e., exposure to actual or threatened death, serious injury or sexual violence according), additional potentially traumatic events affecting daily functioning, and any treatment for traumatic events.Statistical analysisWe assessed prevalence rates of PTSD and frequencies of patients with a history of traumatic events and/or treatment for trauma in our sample, and calculated 95% confidence intervals (95% CI) using the formula CI= p ± 1.96* √(p(1-p)/n). A logistic regression analysis was used to identifypotential predictors to the presence of a clinical diagnosis of PTSD. For this, we considered sex and FSIQ based on previous studies.6 All analyses were two-tailed p-values with statistical significance defined as <0.05 using IBM SPSS software (Statistics 25; Inc., Chicago, IL).ResultsNine patients (8.0%, 95% CI: 3.0%-13.0%) had a clinical diagnosis of PTSD, of whom two were referred to specialized 22q11 clinics for trauma-related problems and treatment (Table 1). Twenty-three (20.5%) of all patients experienced one or more traumatic events according to DSM-5 criteria, with 12 (10.7%) reporting sexual violence, 11 (9.8%) serious injury (including physical abuse), and 4 (3.6%) actual or threatened death. Neglect was